Entera Bio (ENTX) Stock Price & Analysis

ENTX price $3.21 +0.09 +2.88%

Ticker
ENTX
Price
$3.21
Change
+0.09 +2.88%
Market cap ?
$558.29M
P/E ?
-8.94
Dividend yield ?
0.00%
Beta ?
1.41
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
67
Value
57
Quality
44
Growth
100

Stocklytics score rationale: value 57, quality 44, growth 100.

Financials

2016201720182019202020212022202320242025
00500000236000365000571000134000018100042000

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is…

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Entera Bio (ENTX) Stock Price & Analysis

ENTX$3.21+0.09 +2.88%

$558.29M

Market Cap

-8.94

P/E

—

Forward P/E

67

Score

Price History

Financial Summary

Entera Bio Ltd. (ENTX) trades at $3.21, with a market cap of $558.29M and a trailing P/E of -8.94. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2016201720182019202020212022202320242025
00500000236000365000571000134000018100042000

About

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is…